Zhang Dong-xiang, Zhang Yan-kun, Nie Hong-jing, Zhang Ru-jun, Cui Jian-hua, Cheng Yue, Wang Yin-hu, Xiao Zhong-hai, Liu Jia-ying, Wang Hai
Department of Environmental Medicine, Institute of Health and Environmental Medicine, Academy of Military Medical Sciences, Tianjin 300050, China.
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2010 May;26(2):148-52.
To study on the protective effects of new compound codonopsis tablets against acute mountain sickness (AMS).
Forty-five male plain resident soldiers stayed at 1400 m altitude for 3 months were randomly divided into two groups, control (15 men) and treatment group (30 men). Single blind trial was used in this study. The subjects in the two groups took placebo and new compound codonopsis tablets respectively for 5 days before climbing to high mountain, and continued to take for another 10 days until the 3rd day after arriving at 5200 m altitude. On the 1st , 3rd, and 5th day after they arrived at 5200 m altitude, the score and the degree of AMS symptoms of soldiers were followed up and recorded according to State Military Standard GJB1098-91--"Principles of diagnosis and treatment of benign form of acute mountain sickness", heart rate (beats/min) and arterial oxygen saturation (%) were detenrmined. On the 6th day after they arrived at high altitude, forced vital capacity(FVC), forced expired volume in one second(FEV1.0), FEV1% (FEV1.0/FVC), FEF25%-75%, peak expiratory flow (PEF) and maximal voluntary ventilation (MVV) were detected, total frequency of hands cross movement and memory of order numbers test were measured.
Comparison with control, AMS symptoms of treatment group reduced on the 1st, 3rd, and 5th day after arriving at 5200 m high altitude (P < 0.01). The degree of AMS symptoms of treatment group was significantly different from that of control. The proportion of slight symptoms in treatment group was high, and that of relative serious symptoms in control was high. Compared with control, FVC, FEV1.0, FEF25%-75%, PEF and MVV of treatment group increased (P < 0.05, P < 0.01), and Ttis, Ctis of treatment group increased (P < 0.05, P < 0.01), Atime decreased markedly (P < 0.05), there was no statistically significant difference in Etis and Sum between the two groups.
New compound codonopsis tablets could decrease the incidence of AMS, mitigate the symptoms of AMS, and improve breathing function and fingers movement function. New compound codonopsis tablets have an obvious effect on prevention and treatment of acute mountain sickness.
研究新型复方党参片对急性高原病(AMS)的保护作用。
将45名驻平原男性士兵在海拔1400米处停留3个月后随机分为两组,对照组(15人)和治疗组(30人)。本研究采用单盲试验。两组受试者在攀登高山前分别服用安慰剂和新型复方党参片5天,并继续服用10天,直至到达海拔5200米后的第3天。在他们到达海拔5200米后的第1、3和5天,根据国家军用标准GJB1098-91-“良性急性高原病诊断和治疗原则”对士兵的AMS症状评分和程度进行随访记录,测定心率(次/分钟)和动脉血氧饱和度(%)。在他们到达高原后的第6天,检测用力肺活量(FVC)、一秒用力呼气容积(FEV1.0)、FEV1%(FEV1.0/FVC)、FEF25%-75%、呼气峰值流速(PEF)和最大自主通气量(MVV),测量双手交叉运动总次数和数字顺序记忆测试。
与对照组相比,治疗组在到达海拔5200米后的第1、3和5天AMS症状减轻(P<0.01)。治疗组AMS症状程度与对照组有显著差异。治疗组轻度症状比例高,对照组相对严重症状比例高。与对照组相比,治疗组的FVC、FEV1.0、FEF25%-75%、PEF和MVV升高(P<0.05,P<0.01),治疗组的Ttis、Ctis升高(P<0.05,P<0.01),Atime明显降低(P<0.05),两组间Etis和Sum无统计学差异。
新型复方党参片可降低AMS发病率,减轻AMS症状,改善呼吸功能和手指运动功能。新型复方党参片对急性高原病的防治有明显作用。